Takeda Pharmaceutical Company Limited - BDR (TAKP34)

Overview

Takeda Pharmaceutical Company Limited is a globally renowned entity that focuses on the innovation-driven development and distribution of pharmaceutical products. Established in 1781 and based in Tokyo, Japan, Takeda has significantly expanded its footprint beyond its domestic market to serve patients worldwide. The company's operations encompass a broad spectrum of activities from research and development (R&D) through to manufacturing and marketing, including out-licensing partnerships. Takeda distinguishes itself in the pharmaceutical industry through its commitment to addressing complex health challenges in gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. In its pursuit to improve patient care and outcomes, Takeda engages in dynamic collaborations and licensing agreements with other leading entities in the healthcare and biotechnology sectors.

Products and Services

Takeda provides a diverse portfolio of pharmaceutical products across various therapeutic areas. Here is a brief overview of their offerings:

• Entyvio: A key medication in Takeda’s arsenal for managing inflammatory bowel diseases.
• Gattex/Revestive: Designed for the treatment of short bowel syndrome, facilitating nutritional absorption in patients.
• Takecab/Vocinti: Addresses stomach and esophageal ailments, including acid reflux disorders.
• Alofisel: A cell therapy product aimed at treating complex perianal fistulas in Crohn's disease patients.
• Dexilant: Provides relief from heartburn and promotes healing of erosive esophagitis due to acid-mediated gastrointestinal disorders.
• Pantoloc/Controloc: Proton pump inhibitor for the treatment of stomach ulcers and gastroesophageal reflux.
• Adynovate/Adynovi: Engineered for hemophilia A patients, offering protection against bleeding through clot maintenance.
• Feiba: A bypassing agent that helps to manage and prevent bleeding episodes in hemophilia A and B patients with inhibitors.
• Recombinate: Another hemophilia A treatment option focusing on blood clotting factor VIII replenishment.
• Hemofil/Immunate/Immunine: Treats hemophilia A by replacing the missing factor VIII, crucial for effective blood clotting.
• Takhzyro: A preventive treatment for hereditary angioedema, helping to reduce the frequency of attacks.
• Livtencity: Recently introduced to manage and treat viral infections in patients with compromised immune systems.
• Elaprase, Replagal: Offer solutions for patients dealing with Hunter syndrome and Fabry disease, respectively, both categorized under lysosomal storage disorders.
• Advate, Flexbumin: Focus on hemophilia A and critical care management concerning albumin replacement, respectively.
• Vpriv, Gammagard Liquid/Kiovig: Treat Gaucher's disease and provide immunoglobulin therapy for patients with immune deficiencies.
• Hyqvia, Cuvitru: Immunoglobulin products aimed at offering subcutaneous administration options for immune system support.
• Exkivity, Ninlaro, Velcade: Oncology offerings targeting lung cancer and multiple myeloma, showcasing Takeda’s strength in cancer care.
• Azilva-F, Lotriga: Focus on cardiovascular health, particularly in managing blood pressure and cholesterol levels.
• Iclusig, Leuplin/Enantone: Targeted therapies for chronic myeloid leukemia and hormone-related disorders, respectively.
• Adcetris, Vyvanse/Elvanse: Address needs in Hodgkin lymphoma treatment and ADHD management.
• Trintellix, Alunbrig: New era medications for depression and ALK-positive non-small cell lung cancer.